#Isentress

This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.

People who take integrase inhibitors are less likely to stop them due to health issues.

Tivicay (dolutegravir) is a next-generation integrase inhibitor.

This finding came from a larger report indicating that U.S. residents are increasingly taking drugs linked to such symptoms.

Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.

The process toward a creating a healthier lifestyle and discovering my genotype.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Immune reconstitution inflammatory syndrome (IRIS) can occur when individuals with low CD4 counts begin HIV treatment.

More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.

Until now, Isentress (raltegravir) had been available only as a twice-daily drug.

Researchers have succeeded in charting the structure of a tool central to HIV’s effort to splice its genetic code into a human cell’s DNA.

Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.

The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...